Anzeige
Mehr »
Login
Mittwoch, 06.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 120159 | ISIN: US64049M2098 | Ticker-Symbol: NG9
Tradegate
05.11.24
13:36 Uhr
12,900 Euro
-0,100
-0,77 %
1-Jahres-Chart
NEOGENOMICS INC Chart 1 Jahr
5-Tage-Chart
NEOGENOMICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
13,60013,80005.11.
13,50013,80005.11.

Aktuelle News zur NEOGENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiNEOGENOMICS INC - 10-Q, Quarterly Report-
DiNeoGenomics Reports Third Quarter 2024 Results30FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September...
► Artikel lesen
DiNEOGENOMICS INC - 8-K, Current Report6
22.10.NeoGenomics NGS tests gain New York State approval1
08.10.NeoGenomics Unveils AML Express-
24.09.Benchmark maintains Buy rating on Neogenomics stock1
24.09.Expert Ratings For NeoGenomics1
24.09.First Light Asset Management LLC Acquires 480,396 Shares of NeoGenomics, Inc. (NASDAQ:NEO)1
23.09.Natera secures injunction against NeoGenomics assay1
11.09.NeoGenomics, Inc.: NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment320NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September...
► Artikel lesen
30.07.NEOGENOMICS INC - 10-Q, Quarterly Report1
30.07.NeoGenomics, Inc. (NASDAQ:NEO) Q2 2024 Earnings Call Transcript3
29.07.NeoGenomics Non-GAAP EPS of $0.03 beats by $0.03, revenue of $165M beats by $3M3
29.07.NEOGENOMICS INC - 8-K, Current Report2
29.07.NeoGenomics Reports Second Quarter 2024 Results114FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended...
► Artikel lesen
12.07.Injunction against NeoGenomics over RaDaR assay affirmed by appeals court1
12.07.Injunction again NeoGenomics over RaDaR assay affirmed by appeals court1
13.06.NEOGENOMICS INC - S-8, Securities to be offered to employees in employee benefit plans1
24.05.NEOGENOMICS INC - 8-K, Current Report1
10.05.NeoGenomics Earnings Analysis: Q1 Recap-
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1